title: Prognostic and predictive biomarkers in early stage non-small cell lung cancer: tumor based approaches including gene signatures.
abstract: In early stage non-small cell lung cancer (NSCLC) large randomized trials have demonstrated that in patients with radically resected disease adjuvant chemotherapy improves 5-year survival rates. However, a customization of systemic treatment is needed to avoid treatments in patients cured by surgery alone or to justify the use of adjuvant chemotherapy in high risk patients, including those in stage IA. Recently, the possibility of identifying prognostic and predictive factors related to the genetic signatures of the tumor that could affect adjuvant and neo-adjuvant treatment choices for resectable non-small cell lung cancer (NSCLC) has been of interest. This review summarizes the current status and future opportunities for clinical application of genotyping and genomic tests in early NSCLC.
authors: University of Torino, Department of Oncology, Torino, Italy.
authors: Simona
authors: S
authors: Carnio
authors: University of Torino, Department of Oncology, Torino, Italy.
authors: Silvia
authors: S
authors: Novello
authors: University of Torino, Department of Oncology, Torino, Italy.
authors: Mauro
authors: M
authors: Papotti
authors: University of Torino, Department of Oncology, Torino, Italy.
authors: Marco
authors: M
authors: Loiacono
authors: University of Torino, Department of Oncology, Torino, Italy.
authors: Giorgio Vittorio
authors: GV
authors: Scagliotti
keywords: Prognostic and predictive biomarkers; early stages; gene signatures; non-small cell lung cancer (NSCLC)